Pulmonary Arterial Hypertension Market Size

Report ID: GMI1939
   |
Published Date: August 2021
 | 
Report Format: PDF

Download Free PDF

Pulmonary Arterial Hypertension Market Size

Pulmonary Arterial Hypertension (PAH) Market size exceeded USD 6.6 billion in 2020 and is anticipated to grow at a CAGR of 6% between 2021 and 2027. The strong product pipeline and novel drug combination awaiting approval are expected to boost the market growth. Furthermore, pulmonary arterial hypertension is a rare lung disorder that is commonly reported in children. The high proportion of children suffering from untreated PAH offers immense market expansion opportunities and is poised to promote the use of pulmonary arterial hypertension drugs.

 

Pulmonary Arterial Hypertension Market Overview

However, side effects associated with the drugs may negatively influence the market progression. Vasodilators are widely prescribed for the treatment of patients with PAH to open blocked and narrowed blood vessels. Studies report that vasodilators have a number of side effects such as tachycardia, edema, heart palpitations, chest pain, etc. Owing to the substantial side effects associated with the use of vasodilators in chronically ill patients, the U.S. FDA regulates the use of this drug. Further, the PAH drugs that treat high blood pressure and dilate blood vessels require to submit reasonable assurance regarding the safety and effectiveness of the drugs. These drugs require the U.S. FDA approval before commercializing in the market. The FDA drug approval represents a complicated process that demonstrates the safety and efficacy of the drug. Hence, a time-consuming regulatory process and side effects related to the use of PAH drugs might hamper the industry growth during the forecast timeframe.

 

The pulmonary arterial hypertension market has been slightly impacted credited to the COVID-19 and the slender effects of the coronavirus pandemic may remain in the coming years. The impact of coronavirus outbreak on the industry peaked during early 2020 wherein, pulmonary arterial hypertension patients were at a higher risk of suffering from coronavirus. Other challenges including hindrance in diagnostic testing, changed guidelines pertaining to the hospital & emergency care, and interrupted drug supply chain among others had impeded the industry expansion. The pandemic has exhibited the importance of PAH drugs as a response to the increasing number of hospitalized PAH-COVID-19 patients.
 

Authors: Mariam Faizullabhoy, Gauri Wani
Frequently Asked Question(FAQ) :
Why is oral route of administration highly preferred in pulmonary arterial hypertension treatment?
Oral segment had captured a revenue share of over 69% in 2020 owing to higher preference for this route of administration due to the convenience and non-invasiveness.
How will pulmonary arterial hypertension market perform in North America?
Why is Germany a strong growth avenue for pulmonary arterial hypertension market?
How much pulmonary arterial hypertension market worth?
Why are endothelin receptor antagonist drugs in high demand for PAH treatment?
Related Reports
    Authors: Mariam Faizullabhoy, Gauri Wani
    Buy Now
    $4,123 $4,850
    15% off
    $4,840 $6,050
    20% off
    $5,845 $8,350
    30% off
        Buy now
    Premium Report Details

    Base Year: 2020

    Companies covered: 7

    Tables & Figures: 143

    Countries covered: 18

    Pages: 120

    Download Free PDF

    Top